- Home
- AMPY vs CLYM Comparison
AMPY vs CLYM Comparison
Compare AMPY & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- CLYM
- Stock Information
- Founded
- AMPY 2011
- CLYM 2018
- Country
- AMPY United States
- CLYM United States
- Employees
- AMPY N/A
- CLYM N/A
- Industry
- AMPY Oil & Gas Production
- CLYM
- Sector
- AMPY Energy
- CLYM
- Exchange
- AMPY Nasdaq
- CLYM NYSE
- Market Cap
- AMPY 96.4M
- CLYM 101.6M
- IPO Year
- AMPY 2011
- CLYM 2021
- Fundamental
- Price
- AMPY $2.44
- CLYM $1.30
- Analyst Decision
- AMPY Strong Buy
- CLYM
- Analyst Count
- AMPY 3
- CLYM 0
- Target Price
- AMPY $10.00
- CLYM N/A
- AVG Volume (30 Days)
- AMPY 780.8K
- CLYM 160.3K
- Earning Date
- AMPY 05-07-2025
- CLYM 05-14-2025
- Dividend Yield
- AMPY N/A
- CLYM N/A
- EPS Growth
- AMPY N/A
- CLYM N/A
- EPS
- AMPY 0.31
- CLYM N/A
- Revenue
- AMPY $294,680,100.00
- CLYM N/A
- Revenue This Year
- AMPY $17.78
- CLYM N/A
- Revenue Next Year
- AMPY $31.78
- CLYM N/A
- P/E Ratio
- AMPY $7.92
- CLYM N/A
- Revenue Growth
- AMPY 1.72
- CLYM N/A
- 52 Week Low
- AMPY $2.27
- CLYM $1.05
- 52 Week High
- AMPY $8.15
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- AMPY 32.11
- CLYM N/A
- Support Level
- AMPY $2.36
- CLYM N/A
- Resistance Level
- AMPY $2.68
- CLYM N/A
- Average True Range (ATR)
- AMPY 0.27
- CLYM 0.00
- MACD
- AMPY 0.01
- CLYM 0.00
- Stochastic Oscillator
- AMPY 16.41
- CLYM 0.00
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.